Inhibrx (INBX) News Today

$24.97

-0.39 (-1.54%)

(As of 12/8/2023 ET)

Today's Range: $23.83
▼
$25.57
50-Day Range: $14.50
▼
$25.56
52-Week Range: $14.31
▼
$30.71

Volume: 348,372 shs
Average Volume: 407,995 shs
Market Capitalization: $1.18 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $36.50

Source

Source	Headline
	Inhibrx Inc Ordinary Shares INBX morningstar.com - December 9 at 12:42 PM
	Contrasting Cullinan Oncology (NASDAQ:CGEM) & Inhibrx (NASDAQ:INBX) americanbankingnews.com - December 7 at 3:46 AM
	Inhibrx, Inc. (NASDAQ:INBX) Short Interest Up 5.4% in November americanbankingnews.com - December 4 at 2:40 AM
	Inhibrx Inc Ordinary Shares morningstar.com - December 2 at 12:50 PM
	Inhibrx posts Q3 results msn.com - November 10 at 1:16 PM
	Inhibrx, Inc.: Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights finanznachrichten.de - November 10 at 8:16 AM
	Inhibrx Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights finance.yahoo.com - November 9 at 8:10 PM
	Inhibrx reports initial Phase I Ewing sarcoma trial data msn.com - November 4 at 7:27 AM
	Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma finance.yahoo.com - November 2 at 1:13 PM
	Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada finance.yahoo.com - September 19 at 6:29 PM
	Citigroup Inc. Buys 37,822 Shares of Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - September 6 at 4:41 AM
	Inhibrx Shares Rise 15% After Private Placement Financing marketwatch.com - August 29 at 3:34 PM
	Inhibrx Announces $200 Million Private Placement Financing finance.yahoo.com - August 29 at 10:09 AM
	JMP Securities Maintains Outperform Rating for Inhibrx: Here's What You Need To Know markets.businessinsider.com - August 23 at 4:06 PM
	JMP Securities Maintains Inhibrx (INBX) Outperform Recommendation nasdaq.com - August 23 at 9:45 AM
	JMP Securities Reaffirms Their Buy Rating on Inhibrx (INBX) markets.businessinsider.com - August 23 at 4:45 AM
	Inhibrx, Inc. (NASDAQ:INBX) Shares Sold by Barclays PLC marketbeat.com - August 21 at 4:35 AM
	Inhibrx, Inc. (NASDAQ:INBX) Forecasted to Post Q3 2023 Earnings of ($0.96) Per Share marketbeat.com - August 21 at 1:52 AM
	Inhibrx: INBRX-101 Developments Constructive, Market-Generated Data Not So Much msn.com - August 17 at 9:20 PM
	LifeSci Capital Sticks to Their Buy Rating for Inhibrx (INBX) markets.businessinsider.com - August 16 at 6:37 PM
	Inhibrx's (INBX) "Outperform" Rating Reaffirmed at Lifesci Capital marketbeat.com - August 11 at 11:27 AM
	Inhibrx, Inc. Expected to Post FY2023 Earnings of ($3.99) Per Share (NASDAQ:INBX) marketbeat.com - August 11 at 10:00 AM
	Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights finance.yahoo.com - August 8 at 11:11 AM
	Inhibrx, Inc. (NASDAQ:INBX) Stock Position Lowered by Los Angeles Capital Management LLC marketbeat.com - August 8 at 5:49 AM
	Jump Financial LLC Decreases Holdings in Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - August 7 at 7:34 AM
	Virtu Financial LLC Acquires Shares of 10,369 Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - July 28 at 5:47 AM
	Theft in open court: How a fight over lifesaving drugs led to accusations of brazen industrial espionage marketwatch.com - June 27 at 1:19 PM
	GSA Capital Partners LLP Takes Position in Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - June 7 at 7:27 AM
	Inhibrx, Inc. (NASDAQ:INBX) Shares Purchased by UBS Group AG marketbeat.com - June 5 at 4:37 AM
	Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency finance.yahoo.com - May 30 at 1:31 PM
	Inhibrx, Inc. (NASDAQ:INBX) Stake Decreased by Citigroup Inc. marketbeat.com - May 25 at 5:35 AM
	JMP Securities Reiterates Inhibrx (INBX) Market Outperform Recommendation msn.com - May 11 at 9:18 PM
	Inhibrx Inc.: Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights finanznachrichten.de - May 9 at 1:49 PM
	Inhibrx Reports First Quarter 2023 Financial Results and Recent Corporate Highlights finance.yahoo.com - May 8 at 8:47 PM
	Inhibrx, Inc. (INBX) Reports Q1 Loss, Lags Revenue Estimates finance.yahoo.com - May 8 at 8:47 PM
	Strength Seen in Inhibrx, Inc. (INBX): Can Its 9.9% Jump Turn into More Strength? msn.com - May 4 at 4:22 AM
	Los Angeles Capital Management LLC Sells 19,631 Shares of Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - May 3 at 5:26 AM
	INBX Makes Bullish Cross Above Critical Moving Average nasdaq.com - May 1 at 11:26 PM
	Inhibrx, Inc. Expected to Earn FY2023 Earnings of ($3.99) Per Share (NASDAQ:INBX) marketbeat.com - May 1 at 3:21 AM
	Inhibrx Resumes Patient Enrollment In INBRX-109 Studies In Cancer Patients msn.com - April 26 at 8:26 PM
	Inhibrx Initiates a Registration-Enabling Trial of INBRX-101 in AATD and Announces Lift of Partial Clinical Hold on INBRX-109 DR5 Agonist Trials finance.yahoo.com - April 26 at 9:50 AM
	Inhibrx: Undercovered Company With Good Potential seekingalpha.com - April 13 at 11:12 AM
	The past year for Inhibrx (NASDAQ:INBX) investors has not been profitable finance.yahoo.com - March 23 at 8:03 AM
	Inhibrx Stock (NASDAQ:INBX), Analyst Ratings, Price Targets, Predictions benzinga.com - March 13 at 5:39 AM
	Inhibrx Inc.: Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results finanznachrichten.de - March 7 at 6:21 AM
	Inhibrx GAAP EPS of -$0.95 misses by $0.16, revenue of $0.27M misses by $0.52M msn.com - March 6 at 8:21 PM
	Inhibrx Reports Fourth Quarter and Fiscal Year 2022 Financial Results finance.yahoo.com - March 6 at 8:21 PM
	Inhibrx, Inc. (INBX) Reports Q4 Loss, Misses Revenue Estimates finance.yahoo.com - March 6 at 8:21 PM
	Cubist Systematic Strategies LLC Has $1.38 Million Stake in Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - February 10 at 1:17 PM
	SG Americas Securities LLC Takes Position in Inhibrx, Inc. (NASDAQ:INBX) marketbeat.com - February 8 at 4:13 AM

Get Inhibrx News Delivered to You Automatically

INBX Media Mentions By Week

INBX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

INBX
News Sentiment
▼
0.14

0.52
▲
Average
Medical
News Sentiment

INBX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

INBX Articles
This Week
▼
4

1
▲
INBX Articles
Average Week

Get Inhibrx News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:INBX) was last updated on 12/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Inhibrx (INBX) News Today

INBX Media Mentions By Week

INBX Media Sentiment

INBX News Coverage

Related Companies and Tools

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info